Published in Liver Int on August 07, 2008
Causes of adult splanchnic vein thrombosis in the mediterranean area. Mediterr J Hematol Infect Dis (2011) 1.07
Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr (2013) 0.93
Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt. World J Hepatol (2013) 0.80
Budd-Chiari Syndrome in China: A Systematic Analysis of Epidemiological Features Based on the Chinese Literature Survey. Gastroenterol Res Pract (2015) 0.78
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J (2016) 0.75
Combining angioplasty with percutaneous microwave ablation for treating primary Budd-Chiari syndrome associated with hepatocellular carcinoma in two patients: A case report. Oncol Lett (2013) 0.75
Association between JAK2 rs4495487 Polymorphism and Risk of Budd-Chiari Syndrome in China. Gastroenterol Res Pract (2015) 0.75
Budd-Chiari syndrome in a patient of diabetic ketoacidosis. Indian J Endocrinol Metab (2012) 0.75
Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome. BMJ Case Rep (2014) 0.75
Thrombophilia differences in splanchnic vein thrombosis and lower extremity deep venous thrombosis in North America. J Gastroenterol (2012) 0.75
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology (2005) 5.92
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol (2002) 3.72
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol (2010) 2.30
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol (2004) 1.78
Body mass index and the risk for Crohn's disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study). Am J Gastroenterol (2013) 1.77
Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis. Am J Gastroenterol (2006) 1.68
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis (2011) 1.68
Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol (2002) 1.67
Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology (2006) 1.66
Serological markers predict inflammatory bowel disease years before the diagnosis. Gut (2012) 1.64
Factors related to fatigue in patients with cirrhosis before and after liver transplantation. Clin Gastroenterol Hepatol (2011) 1.53
Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology (2010) 1.51
High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology (2005) 1.45
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet (2010) 1.43
Analysis of MAdCAM-1 and ICAM-1 polymorphisms in 365 Scandinavian patients with primary sclerosing cholangitis. J Hepatol (2006) 1.42
[Lhx2 seems to inhibit the development of liver cirrhosis. Gene discovery makes the development of drugs against this enormous health problem possible]. Lakartidningen (2006) 1.39
Are preformed antibodies to biliary epithelial cells of clinical importance in liver transplantation? Liver Transpl (2003) 1.38
Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology (2003) 1.34
Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. Int J Radiat Oncol Biol Phys (2002) 1.31
Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2007) 1.30
Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol (2012) 1.29
Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr (2003) 1.23
Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr (2005) 1.22
Celiac disease and risk of liver disease: a general population-based study. Clin Gastroenterol Hepatol (2006) 1.21
Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology (2007) 1.20
Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2008) 1.19
Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol (2008) 1.19
Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflamm Bowel Dis (2003) 1.16
Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol (2007) 1.14
Characterization of cells in the developing human liver. Differentiation (2005) 1.11
Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology (2013) 1.11
Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol (2010) 1.10
Application of Resource Utilization in Dementia (RUD) instrument in a global setting. Alzheimers Dement (2012) 1.10
Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology (2010) 1.09
Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology (2011) 1.09
Gastrointestinal symptoms in patients with liver cirrhosis: associations with nutritional status and health-related quality of life. Scand J Gastroenterol (2006) 1.09
Quality of life for patients with exacerbation in inflammatory bowel disease and how they cope with disease activity. J Psychosom Res (2008) 1.07
Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis. Liver Int (2007) 1.06
The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int (2006) 1.05
Diet in the aetiology of ulcerative colitis: a European prospective cohort study. Digestion (2008) 1.05
The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids. Int J Colorectal Dis (2007) 1.04
Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials. Am J Gastroenterol (2011) 1.03
Vascular endothelial growth factor (VEGF)--a possible mediator of inflammation and mucosal permeability in patients with collagenous colitis. Dig Dis Sci (2004) 1.02
Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol (2005) 1.01
Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis (2011) 1.00
Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int (2011) 0.99
Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol (2012) 0.99
Increased risk for malignant neoplasms among patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 0.98
Vanishing bile duct-like syndrome in a patient with Hodgkin lymphoma - pathological development and restitution. Acta Oncol (2014) 0.98
High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med (2008) 0.98
Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol (2005) 0.97
Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver Transpl (2003) 0.97
Increased mortality risk in patients with phenotypic hereditary hemochromatosis but not in their first-degree relatives. Gastroenterology (2009) 0.96
Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler (2012) 0.96
A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Ther Clin Risk Manag (2007) 0.94
Increased rate of bone loss at the femoral neck in patients with chronic liver disease. Eur J Gastroenterol Hepatol (2002) 0.94
Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol (2008) 0.94
The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol (2010) 0.93
Accumulation, activation, and survival of neutrophils in ulcerative colitis: regulation by locally produced factors in the colon and impact of steroid treatment. Int J Colorectal Dis (2008) 0.93
Resource use and societal costs for Crohn's disease in Sweden. Inflamm Bowel Dis (2009) 0.93
NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol (2013) 0.91
Coronary artery disease in patients with liver cirrhosis. Dig Dis Sci (2009) 0.91
Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. J Hepatol (2006) 0.91
Beta-defensin production by human colonic plasma cells: a new look at plasma cells in ulcerative colitis. Inflamm Bowel Dis (2007) 0.90
Fecal eosinophil cationic protein as a marker of active disease and treatment outcome in collagenous colitis: a pilot study. Scand J Gastroenterol (2011) 0.90
A novel mechanism of liver allograft rejection facilitated by antibodies to liver sinusoidal endothelial cells. Hepatology (2004) 0.89
CD14(hi)HLA-DR(dim) macrophages, with a resemblance to classical blood monocytes, dominate inflamed mucosa in Crohn's disease. J Leukoc Biol (2013) 0.89
Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease. Int Psychogeriatr (2010) 0.89
Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis. Gastroenterology (2006) 0.89
Gut transit is associated with gastrointestinal symptoms and gut hormone profile in patients with cirrhosis. Clin Gastroenterol Hepatol (2008) 0.89
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. Scand J Infect Dis (2009) 0.88
Gastrointestinal symptoms are associated with hypothalamic-pituitary-adrenal axis suppression in healthy individuals. Scand J Gastroenterol (2007) 0.88
Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol (2010) 0.87
Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointestin Liver Dis (2011) 0.87
Different regulation of eosinophil activity in Crohn's disease compared with ulcerative colitis. J Leukoc Biol (2008) 0.87
Detection of Alzheimer peptides and chemokines in the aqueous humor. Eur J Ophthalmol (2011) 0.87
Pregabalin as a probable cause of acute liver injury. Eur J Gastroenterol Hepatol (2008) 0.86
Reduced susceptibility to dextran sulphate sodium-induced colitis in the interleukin-2 heterozygous (IL-2) mouse. Immunology (2005) 0.86
Peptide YY in gastrointestinal disorders. Peptides (2002) 0.86